
price data provid thomson reuter
number may add due round
initi outperform drink deep tast
clinic stage oncology-focus compani develop nirogacestat
mirdametinib rare tumor potenti leverag lead drug candid
combin studi larger indic partnership beigen
gsk advanc candid nirogacestat gamma secretas inhibitor
phase studi defi treat desmoid tumor mirdametinib mek
inhibitor phase potenti registration-en trial treat
drug candid success studi respect indic
experienc diseas control rate combin ten object
respons median durat treatment nearli month first
studi seven patient year recent studi discontinu
durabl result bear phase expect nirogacestat
best system therapeut option desmoid tumor patient mirdametinib
produc orr patient respons defin
tumor reduct cours dose reduct due grade believ
mirdametinib toler profil lead long-term continu dose
make first choic among physician patient
nirogacestat phase trial mirdametinib potenti registration-
enabl phase studi springwork current enrol phase defi studi
nirogacestat versu placebo desmoid tumor updat possibl
earli stoppag studi power believ good
odd could stop earli although valuat base full enrol
follow compani phase studi reneu mirdametinib potenti
registr enabl compani could provid updat earli
combin studi potenti expand indic combin
nirogacestat belantamab mafodotin gsk nc begin
multipl myeloma patient studi mirdametinib combin braf
inhibitor lifirafenib bgne nc begun patient solid tumor contain
kra nra braf mapk alter
final beigen form joint ventur call mapkur develop
braf kinas inhibitor could enter clinic
activ braf alter current address
therapi interest mapkur
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
clinic stage biotechnolog compani spun compani
two lead program nirogacestat mirdametinib small molecul inhibitor exclus licens
nirogacestat gamma-secretas inhibitor current ph trial defi desmoid tumor patient mirdametinib
inhibitor initi target address neurofibromatosi associ plexiform neurofibrma
ph studi reneu nirogacestat mirdametinib also explor combin
treatment former pair glaxosmithklin belantamab mafodotin anti-bcma antibodi drug conjug
treat relaps refractori multipl myeloma latter pair beigen lifirafenib braf inhibitor
treat ras/raf-mut solid tumor springwork also form joint ventur mapkur beigen
develop broad braf inhibitor intend class ii braf-mut cancer
market size rare non-malign
tumor smaller expect
combo studi larger
either clinic commerci
nirogacestat
mirdametinib gain approv
respect monotherapi
succeed suffici
gain equival market share
efficaci best-in-class profil
attain mirdametinib
gener result superior
competit
initi nirogacestat belantamab mafodotin
combo r/r mm studi raf-mut st
mirdametinib lifirafenib data ras/raf-mut
multipl us/eu niro sale dt mm
mirda sale nsclc endometri cancer
gi tumor sale braf-mut
clinic advanc lead program nirogacestat
result better competit mirda result earli
posit result niro combo studi
gener posit rel rare later-
stage biotech compani w/ de-risk asset
access public market less depend
gener market risk percept investor
clinical-stag biopharmaceut
compani headquart stamford connecticut
compani spun target
rare tumor cancer two lead program
nirogacestat mirdametinib
creat bluematrix
tabl content
tabl content
tabl figur
pipelin catalyst summari
nirogacestat treatment desmoid tumor
nirogacestat treatment multipl myeloma
nirogacestat combin belantamab mafodotin
mirdametinib neurofibromatosi type plexiform neurofibroma
establish efficaci
mirdametinib lifirafenib combo ras/raf aberr solid tumor
overview lifirafenib rational combin
mapkur joint ventur beigen
nirogacestat mirdametinib
licens intellectu properti
financi valuat
tabl figur
tabl content
tabl figur
figur physician prefer system agent treat desmoid tumor
figur clinic trial nirogacestat
figur nirogacestat ph trial outcom desmoid tumor patient
figur nirogacestat ph trial outcom patient desmoid tumor
figur result ph ph trial nirogacestat patient desmoid tumor
figur industry-sponsor clinic trial desmoid tumor
figur suggest algorithm manag multipl myeloma
figur therapi relaps multipl myeloma
figur select bcma-target therapi multipl myeloma
figur -secretas inhibitor limit bcma shed cell surfac
figur gsk clinic studi belantamab mafodotin
figur -secretas inhibitor anti-bcma agent combin program multipl myeloma
figur signal pathway neurofibromin
figur mirdametinib reduc neurofibroma burden month
figur industry-sponsor clinic trial
figur mek inhibitor develop
figur lifirafenib complex kinas domain
figur ra isoform mutat incid cancer type
figur patient respons lifirafenib ph dose expans studi
figur braf mutat class
figur opportun braf mutat class
figur inhibit braf-mut cell
figur licens agreement
pipelin catalyst summari
nirogacestat treatment desmoid tumor
desmoid tumor dt estim annual incid patient us year
primarili affect young adult year age femal predomin dt may
metastas aggress infiltr capac often aris
dna mutat myo- fibroblast lead tumor format lip et al normal cell
maintain tight regul wnt wingless signal pathway figur wnt growth
factor instig cell prolifer absent wnt activ degrad complex form
tumor suppressor protein adenomat polyposi coli apc axin along serine-
threonin kinas control -catenin stabil axin -- catenin complex
phosphoryl form degron-motif recogn ubiquitin
ubiquitin ligas -trcp subsequ proteasom degrad -catenin nuss clever
howev wnt activ increas -catenin level -catenin transloc
nucleu activ target cell factor gene effector wnt cascad
germlin mutat famili adenomat polyposi fap somat mutat apc
result apc loss-of-funct also increas -catenin level drive cell prolifer
activ mutat -catenin gene also effect
regularli found non-apc mutat dt bui kummar notch signal
pathway implic diseas progress via crosstalk wnt signal pathway
-catenin directli regul notch ligand instig aberr notch activ
gamma-secretas cleav notch intracellular domain transloc
nucleu activ gene transcript rodilla et al notch pathway wnt
pathway thought induc express mean prevent apoptosi shang et al
risk factor desmoid tumor includ high estrogen state pregnanc anteced trauma
germlin predisposit famili adenomat polyposi fap syndrom dt
asymptomat symptomat sever pain loss function deform imped vital organ
depend locat though initi present often painless mass major
anatom site outlin figur includ abdomin wall neurovascular bundl
limb shoulder girdl root mesenteri head neck structur mortal
dt patient tumor near mesenteri suscept
diagnosi reli histolog immunohistochemistri sarcoma subtyp dt
identif challeng howev identif -catenin apc mutat often
provid support dt diagnosi
current treatment desmoid tumor
standard medic therapi desmoid tumor exist current treatment often
person patient depend locat aggress tumor patient
suitabl watch-and-wait approach common take account mani desmoid
sueishi et al nakayama et al locat interfer
qualiti life surgeri common strategi though patient experi
recurr altern treatment desir radiat therapi sometim use
despit increas risk develop new aggress cancer treatment interest
thermal ablat grow suitabl desmoid tumor center provid therapi
limit number long-term durabl determin
imatinib gleevec multi-kinas inhibitor target multipl tyrosin kinas kit pdgfr-
 approv fda indic system mastocytosi gastrointestin stromal
tumor dermatofibrosarcoma protuberan among other clinic trial result show
efficaci dt caus off-label adopt physician evidenc
prefer survey among european dt expert schffski requil cann figur
sorafenib nexavar anoth fda-approv thyroid carcinoma renal cell carcinoma
hepatocellular carcinoma multipl tki vegfr c-kit pdgfr also consid off-
label use treat dt timbergen et al sorafenib produc observ efficaci
adapt bui kummar oncotarget wedbush secur inc
gounder thoma journal clinic oncolog
adapt litchman rijn dtrf west coast region patient meet wedbush
figur physician prefer system agent treat desmoid tumor
schffski requil van cann
nirogacestat oral small molecul -secretas inhibitor gsi current
phase develop desmoid tumor figur nirogacestat origin develop
licens gamma-secretas involv notch signal
pathway cleav notch intracellular domain releas cytoplasm
transloc nucleu activ transcript target gene involv
neoplasia therefor inhibit -secretas counter aberr notch activ
addit -secretas substrat notch includ b-cell matur antigen bcma among
other implic diseas multipl myeloma cover
subsequ section report fda grant breakthrough therapi design
august nirogacestat treatment adult patient progress
unresect recurr refractori desmoid tumor also receiv orphan drug
design odd track design ftd fda nirogacestat treatment
dt european commiss recent grant odd nirogacestat treatment soft
adapt https//www sigmaaldrich com wedbush secur inc
nirogacestat investig across multipl clinic trial outlin figur
collect nirogacestat administ patient notabl ph trial
ph trial includ dt patient ph studi enrol
patient solid tumor desmoid tumor total patient evalu
clinic respons use bid dose regimen mg dt patient partial
respons clinic benefit durabl year figur non-dt
patient respons albeit complet respons messersmith et al villalobo et al
hypophosphatemia diarrhea common treatment-
relat advers event trae grade ph studi solid tumor patient
ph studi dt patient evalu mg bid patient achiev
partial respons remain patient stabl diseas kummar et al figur
five patient pr five patient sd remain treatment
month regard safeti hypophosphatemia common trae grade dt
patient ph studi revers oral supplement result ph
ph studi summar figur
figur clinic trial nirogacestat
phase ii trial gamma-
adult
activ
treat
withdrawn due
withdrawn due
pk safeti
biomark research studi
patient
nirogacestat adult
figur nirogacestat ph trial outcom desmoid tumor patient
villalobo et al annal surgic oncolog
figur nirogacestat ph trial outcom patient desmoid tumor
kummar et al journal clinic oncolog
figur result ph ph trial nirogacestat patient desmoid tumor
rang
median time
reach
compani initi potenti registration-en phase defi trial may defi
conduct north america europ two-phas studi double-blind phase
open-label extens phase anticip enrol patient trial
power show month differ nirogacestat placebo
assumpt placebo group experi month top-line data could read
given earlier result expect placebo-control phase defi studi
statist overpow support fda approv interim updat anticip
studi event studi enrol may drive acceler delay
timelin apart primari endpoint secondari endpoint includ orr dor
chang tumor volum safety/toler patient report outcom enrol
expect complet
time top-lin data defi may prolong trial conclus event-depend
also defi may suffici power demonstr clinic benefit nirogacestat
placebo warrant fda approv especi given potenti variabl placebo group trial
enrol may prove challeng anticip also unforeseen patient toxic
remain risk drug class exampl semagacestat -secretas inhibitor develop
alzheim diseas studi end due seriou safeti concern
industry-sponsor clinic trial desmoid tumor summar figur ph
studi novarti imatinib report orr partial respons kasper et al
evidenc tyrosin kinas inhibitor efficaci treat dt current
use off-label sorafenib wide use tki dt best compar
nirogacestat system treatment ph studi sponsor nation cancer institut
orr cr pr report contrast orr placebo group
gounder et al orr compar observ nirogacestat ph trial
though patient sorafenib remain treatment month compar
nirogacestat patient treatment month inde sorafenib toler concern
given patient discontinu treatment due advers event vs placebo group
patient ph nirogacestat studi discontinu therapi due ae recurr
urticari maculopapular rash median ph sorafenib studi reach
month placebo group median follow-up month investig agent
worth mention includ tegavivint privat cellestia biotech
privat tegavivint transduc beta-lik protein inhibitor interfer
bind -catenin -catenin displac degrad promot current ph
studi investig drug safety/toler expect complet
pan-notch inhibitor ph studi began europ patient solid
tumor inclus dt ind clear fda earli year await
see outcom studi whether dt patient becom meaning focu trial
figur industry-sponsor clinic trial desmoid tumor
annual incid desmoid tumor patient us least patient
receiv activ intervent like progress next line therapi
model recurr patient us year long durat
treatment like make commerci opportun greater patient number would
seem support use tradit oncolog model expect price around per month
nirogacestat in-lin recent approv precis oncolog drug turalio
per month rozlytrek per month vitrakvi per month also in-
line approv multipl myeloma drug xpovio per month darzalex per
month pomalyst per month turalio daiichi sankyo nc especi
relev compar given similar turalio target indic tenosynovi giant
cell tumor tgct nirogacestat target desmoid tumor rare benign tumor
expect continu premium price newly-approv novel oncolog drug
model address patient year nirogacestat monotherapi desmoid
tumor compris primari recurr patient expect
cure surgic resect wait-and-se approach total revenu per patient
expect highli variabl mortal rate rel low patient
potenti therapi year median durat treatment ph
cycl durat total revenu per patient averag could amount
posit toler efficaci nirogacestat may warrant even longer treatment durat
patient desmoid tumor opportun could larger current estim
nirogacestat treatment multipl myeloma
mm hematolog cancer termin differenti monoclon plasma cell bone
marrow extra-medullari site estim newly-diagnos us
patient approxim patient die diseas five-year surviv
rate approxim seer estim treatment mm hing patient elig
autolog hematopoiet stem cell transplant asct whether standard
intermedi high risk diseas suggest algorithm manag multipl
myeloma current accept treatment regimen depict figur
like daratumumab elotuzumab chemotherapi multipl
combin agent shown vari degre clinic activ gener
integr asct patient fit transplant although use asct
therapi significantli improv clinic outcom diseas remain incur
major patient expect relaps sonnerveld broijl chim et al
xpoviotm select inhibitor nuclear export sine karyopharm op recent
approv use combin dexamethason r/r mm penta-refractori patient
refractori least two pi least two imid mab
develop mm therapi recent shift target b-cell matur antigen
bcma target express exclus plasma cell over-express mm cell
collag bcma-target therapi mm recent assembl mullard
compound bispecif antibodi bsab bispecif cell engag bite
figur suggest algorithm manag multipl myeloma
krd carfilzomib lenalidomid dexamethason vrd bortezomib lenalidomid dexamethason
figur therapi relaps multipl myeloma
lenalidomid pomalidomid mab daratumumab elotuzumab
adapt kumar et al wedbush secur inc
figur select bcma-target therapi multipl myeloma
adapt mullard wedbush secur inc
nirogacestat combin belantamab mafodotin
belantamab mafodotin afucosyl anti-bcma equip
monomethyl auristatin payload develop gsk advanc anti-bcma
partnership springwork gsk aim combin nirogacestat belantamab
mafodotin treat mm gamma-secretas shown cleav bcma cell
surfac behav decoy receptor -secretas inhibitor abl decreas
free bcma block bcma releas cell surfac laurent et al figur
importantli recent work shown gsi dramat increas percent
myeloma cell test posit bcma also increas cell surfac densiti
result part ph studi belantamab mafodotin demonstr orr
monotherapi patient median prior line therapi trudel et al although
orr numer lower celgen car-t orr
in-lin month mpf
belantamab mafodotin vs month mpf raje et al furthermor
belantamab easier manufactur rather engin autolog cell therapi
august gsk announc pivot ph studi met primari endpoint
compani plan begin regulatori file year-end expect data
upcom scientif meet like decemb
figur -secretas inhibitor limit bcma shed cell surfac
collabor gsk origin announc june compani plan
initi phase combin studi belantamab mafodotin nirogacestat apart
nirogacestat manufactur trial expens born gsk trial consist
dose-escal stage follow dose expans phase intend patient popul
apart belantamab mafodotin nirogacestat combo gsk also plan explor
combin agent multipl benchmark nirogacestat
belantamab combin figur
figur gsk clinic studi belantamab mafodotin
adapt glaxosmithklin press releas august
second common hematolog malign drug sale mm treatment major
market reach expect grow wilcock
webster roughli newly-incid last-lin mm pt year us could
address nirogacestat combin use estim cycl therapi per
patient total averag annual patient revenu could despit shorter treatment
durat compar patient desmoid tumor sheer number last-lin mm patient
contribut meaning valuat attribut see belantamab
mafodotin import partner leverag nirogacestat -secretas activ
belantamab mafodotin demonstr efficaci like near-term approv monotherapi
-secretase/bcma combin earli develop stage outlin figur
januari novarti nv nc in-licens -secretas inhibitor ayala
privat plan pair inhibitor anti-bcma therapi mm
nation cancer institut nci fred hutchinson cancer research center conduct
studi celg anti-bcma car-t therapi lli
figur -secretas inhibitor anti-bcma agent combin program multipl
mirdametinib neurofibromatosi type plexiform
one individu type neurofibromatosi autosom domin disord
caus mutat gene chromosom aris equal either famili
inherit de novo mutat gutmann et al encod neurofibromin
encompass domain structur similar gtpase activ protein
involv neg regul ra gtp-bound ra switch protein drive
cell prolifer oncogenesi neurofibromin catalyz inactiv ra
convers ra bound gtp figur neurofibromin inactiv turn
prolif pathway diseas often diagnos childhood often defin
abnorm scoliosi dysplasia behavior abnorm figur -pn progress
age vari rate patient fold like develop malign compar
gener popul among neurofibroma two major type dermal sub-
cutan plexiform former small nodule-lik tumor
surfac skin tend grow larger develop insid bodi may
wrap around nerv blood vessel structur becom cancer
half patient friedman current approv
therapi diseas given intim involv nerv tendenc regrow
neurofibroma and/or manifest
long-term efficaci surgic resect limit chemotherapi and/or radiat
therapi intervent consid target therapi mek
inhibitor mtor inhibitor imatinib current investig clinic trial could
manag approach appropri tailor characterist
figur signal pathway neurofibromin
mirdametinib potent alloster mek inhibitor licens
springwork develop monotherapi figur increas ra
signal mapk pathway activ due defunct neurofibromin throttl
mitogen-activ protein kinas kinas mapk/erk kinas mek inhibit reduc
pn proliferation/neoplasia use downstream mek inhibitor mirdametinib
app nm behav non-
mirdametinib exhibit high potenc activ ki
competit atp sebolt-leopold et al fda grant mirdametinib orphan
drug design odd track design
establish efficaci
establish potenti mirdametinib mous model use
preclin studi mice administ mg/kg/day mirdametinib show
delay neurofibroma neoplasia compar vehicl control figur dose
similar nirogacestat mirdametinib administ patient across multipl
clinic trial outlin figur studi led univers alabama birmingham
patient inoper grow symptomat pn experienc show
orr cycl compar orr age-match histor control
patient studi receiv bid mg bid mirdametinib
report manag safeti profil patient studi dose reduct
due advers event grade treatment-emerg advers event
patient one patient discontinu treatment due grade rash
figur mirdametinib reduc neurofibroma burden month
springwork recent began recruit patient reneu potenti registr phase
single-arm studi mirdametinib pediatr adult patient
studi aim enrol patient across site north america dose
cycl cycl week week bid mg bid object respons
safety/toler durat respons qualiti life measur updat studi
expect earli
studi primari endpoint secondari endpoint
investig agent current evalu figur howev
studi encount challeng patient accrual clinic activ
toxic potenti direct competit springwork
includ astrazeneca selumetinib novarti trametinib array/pf binimetinib mek
selumetinib display high respons rate investigator-initi studi
patient treat ph studi experienc pr rate ph studi report
pr bid bid bid
respect overal median durat treatment cycl
ph trial month ph studi ph mirdametinib trial report
pr design differ like detract magnitud report effect
make difficult compar orr across trial exampl patient volumetr
reduct pn cycl remov studi patient
volumetr reduct pn cycl yet selumetinib ph studi allow patient
remain studi longer benefit pr confirm month
later pr patient treatment less month selumetinib studi also
enrol patient median age year old ph trial respect
median age patient ph mirdametinib studi year old children
often exhibit rapid tumor growth compar adult like
differ respons trajectori adult patient expect regulatori approv selumetinib
younger averag age selumetinib studi may limit use adult
patient springwork reneu trial expect compani use similar studi design
selumetinib ph studi benefit better captur patient respons mirdametinib
note array biopharma file lawsuit astrazeneca claim initi licens
selumetinib limit oncolog indic outsid astrazeneca
ph trial trametinib pediatr patient show pr across
dose escal expans cohort studi mccowag et al trametinib
alreadi fda approv melanoma non-smal cell lung cancer nsclc anaplast thyroid
cancer atc trade name mekinist drug avail liquid formul may
prefer pediatr patient lack adult enrol trametinib trial may limit use
pediatr patient binimetinib ph studi sponsor univers alabama
birmingham follow similar protocol mirdametinib ph studi
see opportun mirdametinib differenti compet mek inhibitor
amen safeti profil better toler mirdametinib ph studi report
three treatment-rel event one patient two pain event five dose
reduct rash nausea fatigu pain hand
selumetinib ph studi requir dose reduct five patient discontinu
four discontinu possibl due studi drug expans cohort
trametinib ph trial patient experi trae one patient
discontinu due trae common trae studi group paronychia
rash given prolong treatment durat necessari patient
drug toxic profil like key characterist consid see mirdametinib
well posit among peer respect
figur industry-sponsor clinic trial
figur mek inhibitor develop
occurr rate peopl half like pn model
patient requir system therapi enter treatment pool per year
us patient like nirogacestat believ price per month line market
standard given need extend durat treatment patient maintain
diseas control compet agent shown median durat treatment around
cycl total revenu per patient could approach alon us eu market
mirdametinib add valuat
mirdametinib lifirafenib combo ras/raf aberr solid tumor
overview lifirafenib rational combin
septemb enter collabor beigen bgne nc develop
mirdametinib combin bgne lifirafenib fuse tricycl benzoimidazol compound
capabl inhibit hetero- homo-dimer form raf raf dimer epiderm
growth factor receptor egfr tang et al figur mutat ra favor gtpase
thu constitut ra activ associ hyperprolif
develop disord cancer figur summar ra mutat incid rate cancer
type kra mutat occur frequent ra isoform hra nra
cancer common codon prior lewi matto vertic
inhibit mek mirdametinib raf lifirafenib combin
complet shut ras-raf-mek-erk signal pathway cell prolifer figur
figur lifirafenib complex kinas domain
figur ra isoform mutat incid cancer type
adapt prior lewi matto wedbush secur inc
ph dose expans result lifirafenib monotherapi mg qd
raf- ras-mut solid tumor patient clinic activ multipl tumor type figur
desai et al result consist dose-find portion studi
report year earlier orr cr pr dcr desai et al
thirty-f percent patient experienc grade advers event notabl
hypertens thrombocytopenia safety/toler lifirafenib gener
toler studi given improv seen combin mek inhibitor previou
gener braf inhibitor long et al larkin et al robert et al see
rational suggest ad benefit combin mirdametinib lifirafenib
figur patient respons lifirafenib ph dose expans studi
least three notabl mek/raf-dim inhibitor combin current
investig clinic trial novarti conduct ph trial trametinib mek
raf-dim patient kras/braf-mut nsclc kras-mut melanoma
interim result trial disclos estim primari complet end
sept monotherapi data advanc solid tumor cancer patient mapk
pathway aberr limit respons pr janku et al median
durat respons week patient discontinu due diseas
progress effect braf craf inhibit signific activ
araf monaco et al
genentech report develop mek/raf-dim inhibitor combo belvarefenib raf-
dimer cobimetinib mek sinc may though compani
provid result cobimetinib fda approv nov combin treatment
vemurafenib melanoma patient braf mutat vemurafenib
earlier gener raf inhibitor efficaci monomer sharma et
al belvarefenib display efficaci monotherapi across nine dose cohort
two ph studi nras-mut melanoma kras-mut sarcoma braf-
mutant gist melanoma patient pr et al though limit
patient number nras-mut melanoma patient appear fare favor
recent esmo meet barcelona spain array biopharma interim ph data
encorafenib braf inhibitor binimetinib mek inhibitor cetuximab egfr inhibitor triplet
therapi encorafenib cetuximab doublet therapi evalu control group
cetuximab combin either irinotecan folfiri folin acid fluorouracil
irinotecan colorect cancer patient kopetz et al
result suggest improv benefit triplet therapi mo month
orr control mo month orr doublet therapi mo month
similar genentech studi enrol
patient limit particularli given braf-mutant-posit colorect cancer patient
harbor mutat dankner et al howev studi reiter
lifirafenib uniqu advantag broad inhibit braf mutant egfr inhibit kotani et
mirdametinib lifirafenib ph combo trial treat advanc refractori solid tumor
patient relev mapk pathway genet aberr initi may australia
recent ind clear fda allow studi site open us enrol
trial first stage trial dose find mirdametinib mg mg qd
lifirafenib mg qd second stage evalu recommend phase dose
cohort repres intend popul non-smal cell lung cancer
endometri cancer patient kra mutat data updat trial isnt expect
late beigen lead ph studi develop cost split
springwork
see combin regimen lifirafenib opportun address addit
pt year us includ nsclc endometri cancer gi tumor
pancreat cancer colorect cancer biliari tract cancer base preval said
cancer ra mutat rate also take account biomark test rate
remov patient may elig surgic resect model assum treatment
durat around month total revenu per patient could amount
model project mirdametinib lifirafenib combin reach market reach
annual sale
mapkur joint ventur beigen
springwork togeth beigen form mapkur june independ joint
ventur dedic develop oral select small-molecul inhibitor
activ braf mutat braf fusion springwork invest minor stake
non-control interest oblig increas ownership upon first
anniversari mapkur springwork hold right develop commerci
outsid asia includ japan
braf mutat common oncogen kinas aberr cancer present
melanoma case thyroid cancer case case nsclc case
dankner et al mutat braf classifi three differ way infer drug
respons base kinas activ ras-depend dimer statu figur
class mutat alter caus high kinas activ fold
constitut signal due monomer conform chang imit dimer
form class ii mutat mutat instead commonli alter
activ segment disrupt braf auto-inhibit state increas intrins kinas
activ class ii mutant signal ras-independ dimer intermedi high
kinas activ class mutant also mutat basal kinas activ lower
wild-typ braf propos function promot dimer kinas
domain dynam restrict multipl braf inhibitor found effect
patient class mutat particularli melanoma durabl short year durrant
morrison braf fusion describ capabl autophosphoryl due
lost ra bind domain creat constitut activ protein turner et al
instanc braf fusion therapeut target heterogen increas
describ earlier uniqu inhibit braf activ mutat
fusion figur outlin potenti address cancer patient vari braf
figur braf mutat class
figur opportun braf mutat class
inhibit velv similar potenc demonstr
erk signal confer resist dabrafenib promot raf dimer bgb-
reduc
phosphoryl erk perk inhibit monomer cell observ
test raf inhibitor test vemurafenib dabrafenib
activ dimer figur
figur inhibit braf-mut cell
adapt wang et al
mapkur move forward adapt ph dose escal expans trial bgb-
start australia ind fda expect file shortli thereaft
investig us springwork hold one seat mapkur joint steer committe
one seat mapkur board director aim contribut clinic develop
believ like undisclos preclin program major pharmaceut compani
target oncolog compani similar earli stage develop
preclin data support standout dual potenc monomer
dimer activ braf mutant see mapkur real contend space
approxim nsclc melanoma pt harbor class braf mutat
respect therefor would address therapi total amount
address new pt us year command price around
per month per patient treatment durat around month total revenu per patient
could amount averag also model opportun braf-
mutant-posit advanc solid tumor among newly-incid pt advanc
solid tumor approxim biomarker-posit therefor repres addit
address pt togeth contribut valuat
nirogacestat mirdametinib
springwork use third-parti contract manufactur organ cmo manufactur
two lead asset nirogacestat mirdametinib agreement asymchem
laboratori inc cover product nirogacestat drug substanc agreement
patheon inc cover product drug substanc midametinib drug product
program produc patheon contract manufactur organ held strictli
complianc current good manufactur practic cgmp requir current
product limit scale preclin studi clinic trial springwork anticip
cmo abl scale commercial-scal product level
need aris commercial-scal product agreement current place
licens intellectu properti
springwork spun made initi equiti invest
compani execut vp/chief patient offic springwork board
director springwork licens two lead candid nirogacestat mirdametinib
opportun year licens acquir select
addit compound specifi term agreement nirogacestat
mirdametinib outlin figur regard nirogacestat springwork exclus
world-wide right research develop manufactur commerci drug
indic alzheim diseas breast cancer prostat cancer springwork
pay commerci mileston tier royalti sale percentag
mid-singl digit low exclus world-wide licens mirdametinib similar
nirogacestat though limit indic pursu mirdametinib
agreement restrict conduct clinic trial mek inhibitor
year except mek inhibitor own control acquir
figur licens agreement pfizer
digit
digit
develop
cancer prostat
limit pfizer
inhibitor
collabor agreement beigen
springwork enter clinic collabor beigen bgne august develop
mirdametinib combin beigen lifirafenib raf dimer inhibitor ph studi
patient advanc refractori solid tumor beigen take lead administ
trial springwork must perform fix dose formul activ compani
individu respons provid respect compound trial parti
equal represent steer meet manag trial cost studi
split equal ph trial complet compani abl negoti
expans studi joint commerci opportun good-faith
collabor agreement glaxosmithklin
springwork enter collabor agreement gsk june evalu
nirogacestat combin belantmab mafodotin bcma ph studi r/r mm
patient apart manufactur suppli nirogacestat gsk bear respons
cost associ studi joint develop committe equal repres
compani manag collabor compani opportun negoti
new term upon trial complet specifi period follow effect date
agreement springwork bar pair nirogacestat bcma-bind agent
preclin clinic studi
exclus licens agreement springwork patent right three us
patent patent foreign jurisdict australia canada china franc germani
spain japan key us patent cover nirogacestat composit matter expir
includ patent term adjustments/extens relev foreign counterpart
patent upon obtain regulatori approv springwork expect orphan drug exclus
nirogacestat treat desmoid tumor provid nirogacestat market protect seven
year us ten year europ fda alreadi grant nirogacestat
orphan drug design odd desmoid tumor european commiss recent
grant odd nirogacestat treatment soft tissu sarcoma
nirogacestat springwork licens agreement provid right two patent
us patent abroad australia canada china franc germani spain
japan patent expir patent term adjust us may provid
addit year springwork look orphan drug exclus seven year
market protect us ten year europ fda alreadi grant mirdametinib
odd european commiss grant odd
saqib found member compani execut team launch
serv chief financi offic chief busi offic
appoint ceo join springwork saqib chief
busi offic execut vice presid chief
strategi prior saqib also held role credit
suiss manag director invest bank saqib
hold bachelor degre mcgill univers columbia law
franci appoint cfo springwork august join
decad experi cfo forest laboratori compani
acquir actavi franci also bristol-my squibb
serv vice presid financ oper plan among
role franci account audit partner deloitt
year franci also serv board member concordia intern
franci receiv mba stern school busi nyu
bachelor scienc degre villanova univers
stephen join springwork start act head
stephen also execut partner orbim prior springwork
stephen co-found alexion pharmaceut alexion
year role includ execut vice presid head stephen also
experi regeneron pharmaceut senior leadership discoveri
research stephen receiv ph loyola univers
jen appoint chief medic offic springwork prior
springwork jen senior vice presid head global medic affair
alexion pharmaceut jen also work glaxo smith kline vice
presid head global medic affair merck medic director
region medic director jen began career ipsen scandinavia
also serv manag director jen receiv
copenhagen busi school univers copenhagen
badreddin appoint chief busi offic springwork
join springwork badreddin co-found edgewis therapeut
serv chief oper offic advisor badreddin also
orbim serv oper vice presid privat equiti
orbim badreddin co-found silverback
therapeut chief busi offic head corpor
develop badreddin also manag consult bain
compani badreddin receiv bachelor integr studi degre
weber state univers ms ph stanford univers
act head
financi valuat
june cash cash equival rais
issuanc public share septemb compani manag guid
annual cash burn rate project suffici runway
research develop expens first half gener
administr expens period
initi coverag outperform rate price target pt deriv
sum-of-part valuat swtx main clinic near-clin program multipl
estim us eu sale nirogacestat primari recurr desmoid tumor
discount back multipl estim us eu sale nirogacestat
multipl myeloma discount back multipl estim us eu sale
mirdametinib nsclc endometri cancer gi tumor discount back
plu multipl swtx share estim us eu sale class
braf-mutant-posit nsclc melanoma advanc solid tumor discount back
valuat tabl
product expens oper incom interest incom non-op incom incom incom incom ep share dilut share thousand except per share data compani data wedbush secur inc estim valuat
multipl us/eu niro sale dt mm mirda sale nsclc endometri cancer gi tumor
sale braf-mut cancer discount back
risk attain price rate
failur achiev clinic regulatori success program addit failur meet estim launch
david nierengarten jeffrey la rosa matthew barcu certifi view express report accur reflect
person opinion directli indirectli receiv compens payment connect
specif recommend view contain report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
octob
octob
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
